Biological
Tebotelimab clinical trials
Also written MGD013.
- studies test it
- 6
- open now
- 0
- in phase 3
- 2
- first study started
- 2017
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
6 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 4
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tebotelimab is read from its arms, and is right about nine times in ten.
Testing it · 6
- Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerCompletedPhase 2/3MacroGenicsNCT04082364Written as Tebotelimab
- MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer PatientsTerminatedPhase 1/2Zai Lab (Shanghai) Co., Ltd.NCT04212221Written as MGD013 monotherapy
- A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With MelanomaTerminatedPhase 1Zai Lab (Shanghai) Co., Ltd.NCT04653038Written as MGD013
- A Study of MGD013 in Patients With Unresectable or Metastatic NeoplasmsCompletedPhase 1MacroGenicsNCT03219268Written as tebotelimab 1 mg
- Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck CancerTerminatedPhase 2MacroGenicsNCT04634825Written as Tebotelimab
- Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and NeckWithdrawnPhase 2/3MacroGenicsNCT04129320Written as MGD013
Codes
What other systems call tebotelimab · ClinicalTrials.gg INT017142
- UNII (FDA) L62556GPXBTEBOTELIMABOne source FDA
- NCI Thesaurus C143957TebotelimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | L62556GPXB | TEBOTELIMAB | One source FDA |
| NCI Thesaurus | C143957 | Tebotelimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.